Cannabidiol 133 mg + Cannabigerol 66 mg + Tetrahydrocannabinol 4 mg
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Cannabidiol 133 mg + Cannabigerol 66 mg + Tetrahydrocannabinol 4 mg, covering 2025-02-24 to 2025-02-24. Get the full timeline:
Most recent: Clinical Trial Update: Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine - [Phase 2, Phase 3]